Esketamine (Spravato) is Therapeutic Goods Administration (TGA) approved treatment for Treatment Resistant Depression which is defined as depression that persists despite adequate trials of two or more antidepressants.
Spravato is a nasal spray form of ketamine and has been shown to be safe and effective in the treatment of severe depression. However, it is a restricted medication and can only be delivered at certified treatment centers, like Mindsight Clinic.
Esketamine is supported by the Department of Veterans Affairs, and some Workcover clients with approval from the insurer.
*Currently there is no PBS listing for Esketamine for private patients, however subsidies may be available for selected patients.
*Esketamine will be PBS listed as per 1 May 2025 for Treatment Resistant Depression.
To find out more about Spravato, you can download the patient guide here:
Spravato Patient Guide (pdf)
DownloadMindsight Clinic Esketamine referral form (fillable PDF) for clinicians
Referral Form (pdf)
DownloadWe use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.